Changing The Future Of Respiratory Patient Care

John Power, CEO and Founder, Aerogen shares insights with Prathiba Raju about the respiratory medicine market in India and how Aerogen products are making a difference in the Indian market

- Prathiba Raju

How do you intend to change the future of respiratory patient care? How does your product profile compliment Indian conditions?

India has 18 percent of the world’s population but 32 percent of the global burden of respiratory disease. This is the second highest cause of death in India in 2017. Till date, over seven million acute care patients around the globe have benefitted from treatment utilizing Aerogen products. Our ambition is to bring this benefit to more patients in India.

How has the Aerogen’s aerosol drug delivery technology transformed the emergency medicine in hospitals, worldwide and particularly in India?

I would like to refer to a recent study conducted in St John Hospital and Medical Centre, Detroit, where it showcased that by using Aerogen nebulizer, there was 32 percent reduction in hospital admissions and a 75 percent reduction in required medication when compared to a standard jet nebulizer. This data extolls the benefits of Aerogen Ultra, a new product which helps in treating ER patients faster and more effectively.

As per the US-based ‘Transparency Market Research', India’s nebulizer market is to reach Rs 4,703.4 million in 2023 from Rs 575.6 million in 2014. Amidst this, what opportunities are you looking at for Aerogen? Currently, where does the company stand in the market? What scope do you see for your company in the nebulizer market in India?